{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:36:01Z","timestamp":1793496961003,"version":"4.5.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T00:00:00Z","timestamp":1638144000000},"content-version":"vor","delay-in-days":760,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Health-related quality of life (HRQoL) has been shown to be a prognostic factor for cancer survival in randomized clinical trials and observational \u201creal-world\u201d cohort studies; however, it remains unclear which HRQoL domains are the best prognosticators. The primary aims of this population-based, observational study were to (a) investigate the association between the novel European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core30 (QLQ-C30) summary score and all-cause mortality, adjusting for the more traditional sociodemographic and clinical prognostic factors; and (b) compare the prognostic value of the QLQ-C30 summary score with the global quality of life (QoL) and physical functioning scales of the QLQ-C30.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>Between 2008 and 2015, patients with cancer (12 tumor types) were invited to participate in PROFILES disease-specific registry studies (response rate, 69%). In this secondary analysis of 6,895 patients, multivariate Cox proportional hazard regression models were used to investigate the association between the QLQ-C30 scores and all-cause mortality.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In the overall Cox regression model including sociodemographic and clinical variables, the QLQ-C30 summary score was associated significantly with all-cause mortality (hazard ratio [HR], 0.77; 99% confidence interval [CI], 0.71\u20130.82). In stratified analyses, significant associations between the summary score and all-cause mortality were observed for colon, rectal, and prostate cancer, non-Hodgkin lymphoma, chronic lymphocytic leukemia, and multiple myeloma. The QLQ-C30 summary score had a stronger association with all-cause mortality than the global QoL scale (HR, 0.82; 99% CI, 0.77\u20130.86) or the physical functioning scale (HR, 0.81; 95% CI, 0.77\u20130.85).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In a real-world setting, the QLQ-C30 summary score has a strong prognostic value for overall survival for a number of populations of patients with cancer above and beyond that provided by clinical and sociodemographic variables. The QLQ-C30 summary score appears to have more prognostic value than the global QoL, physical functioning, or any other scale within the QLQ-C30.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2019-0348","type":"journal-article","created":{"date-parts":[[2019,10,31]],"date-time":"2019-10-31T19:35:48Z","timestamp":1572550548000},"page":"e722-e732","source":"Crossref","is-referenced-by-count":215,"title":["The EORTC QLQ-C30 Summary Score as Prognostic Factor for Survival of Patients with Cancer in the \u201cReal-World\u201d: Results from the Population-Based PROFILES Registry"],"prefix":"10.1093","volume":"25","author":[{"given":"Olga","family":"Husson","sequence":"first","affiliation":[{"name":"Department of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands"},{"name":"Division of Clinical Studies, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belle H.","family":"de Rooij","sequence":"additional","affiliation":[{"name":"Center of Research on Psychology in Somatic diseases, Department of Medical and Clinical Psychology, Tilburg University, Tilburg, The Netherlands"},{"name":"The Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacobien","family":"Kieffer","sequence":"additional","affiliation":[{"name":"Department of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Oerlemans","sequence":"additional","affiliation":[{"name":"The Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floortje","family":"Mols","sequence":"additional","affiliation":[{"name":"Center of Research on Psychology in Somatic diseases, Department of Medical and Clinical Psychology, Tilburg University, Tilburg, The Netherlands"},{"name":"The Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil K.","family":"Aaronson","sequence":"additional","affiliation":[{"name":"Department of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winette T.A.","family":"van der Graaf","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Netherlands Cancer Institute \u2013 Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands"},{"name":"Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lonneke V.","family":"van de Poll-Franse","sequence":"additional","affiliation":[{"name":"Department of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands"},{"name":"Center of Research on Psychology in Somatic diseases, Department of Medical and Clinical Psychology, Tilburg University, Tilburg, The Netherlands"},{"name":"The Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,10,31]]},"reference":[{"key":"2021122510314099300_R1","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jval.2015.02.018","article-title":"Methods for developing patient-reported outcome-based performance measures (PRO-PMs)","volume":"18","author":"Basch","year":"2015","journal-title":"Value Health"},{"key":"2021122510314099300_R2","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1477-7525-4-79","article-title":"Guidance for industry: Patient-reported outcome measures: Use in medical product development to support labeling claims: Draft guidance","volume":"4","author":"U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health","year":"2006","journal-title":"Health Qual Life Outcomes"},{"key":"2021122510314099300_R3","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1046\/j.1524-4733.2003.65309.x","article-title":"Incorporating the patient's perspective into drug development and communication: An ad hoc task force report of the Patient-Reported Outcomes (PRO) Harmonization Group meeting at the Food and Drug Administration, February 16, 2001","volume":"6","author":"Acquadro","year":"2003","journal-title":"Value Health"},{"key":"2021122510314099300_R4","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1158\/1078-0432.CCR-15-2035","article-title":"Focusing on core patient-reported outcomes in cancer clinical trials: Symptomatic adverse events, physical function, and disease-related symptoms","volume":"22","author":"Kluetz","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2021122510314099300_R5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/jama.1995.03520250075037","article-title":"Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes","volume":"273","author":"Wilson","year":"1995","journal-title":"JAMA"},{"key":"2021122510314099300_R6","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/cncr.28382","article-title":"A global analysis of multitrial data investigating quality of life and symptoms as prognostic factors for survival in different tumor sites","volume":"120","author":"Quinten","year":"2014","journal-title":"Cancer"},{"key":"2021122510314099300_R7","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S1470-2045(09)70200-1","article-title":"Baseline quality of life as a prognostic indicator of survival: A meta-analysis of individual patient data from EORTC clinical trials","volume":"10","author":"Quinten","year":"2009","journal-title":"Lancet Oncol"},{"key":"2021122510314099300_R8","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1200\/JCO.2007.13.3439","article-title":"The prognostic significance of patient-reported outcomes in cancer clinical trials","volume":"26","author":"Gotay","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122510314099300_R9","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1002\/cncr.31556","article-title":"Quality of life as a prognostic indicator of survival: A pooled analysis of individual patient data from canadian cancer trials group clinical trials","volume":"124","author":"Ediebah","year":"2018","journal-title":"Cancer"},{"key":"2021122510314099300_R10","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1200\/JOP.2015.004432","article-title":"Big data infrastructure for cancer outcomes research: Implications for the practicing oncologist","volume":"11","author":"Meyer","year":"2015","journal-title":"J Oncol Pract"},{"key":"2021122510314099300_R11","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1477-7525-7-102","article-title":"Quality of life data as prognostic indicators of survival in cancer patients: An overview of the literature from 1982 to 2008","volume":"7","author":"Montazeri","year":"2009","journal-title":"Health Qual Life Outcomes"},{"key":"2021122510314099300_R12","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.ejca.2004.01.014","article-title":"Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer","volume":"40","author":"Efficace","year":"2004","journal-title":"Eur J Cancer"},{"key":"2021122510314099300_R13","doi-asserted-by":"crossref","first-page":"5617","DOI":"10.1158\/1078-0432.CCR-16-1529","article-title":"EORTC Quality of Life Group. Focusing on core patient-reported outcomes in cancer clinical trials-letter","volume":"22","author":"Groenvold","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2021122510314099300_R14","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jclinepi.2015.08.007","article-title":"Replication and validation of higher order models demonstrated that a summary score for the EORTC QLQ-C30 is robust","volume":"69","author":"Giesinger","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"2021122510314099300_R15","first-page":"76","article-title":"Modeling quality of life in cancer patients as a unidimensional construct","volume":"65","author":"Pagano","year":"2006","journal-title":"Hawaii Med J"},{"key":"2021122510314099300_R16","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jgo.2017.07.007","article-title":"Sociodemographic, socioeconomic, and clinical determinants of survival in patients with cancer: A systematic review of the literature focused on the elderly","volume":"9","author":"Galvin","year":"2018","journal-title":"J Geriatr Oncol"},{"key":"2021122510314099300_R17","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.ejca.2011.04.034","article-title":"The Patient Reported Outcomes Following Initial treatment and Long term Evaluation of Survivorship registry: Scope, rationale and design of an infrastructure for the study of physical and psychosocial outcomes in cancer survivorship cohorts","volume":"47","author":"Poll-Franse","year":"2011","journal-title":"Eur J Cancer"},{"key":"2021122510314099300_R18","volume-title":"International Classification of Diseases for Oncology","author":"Fritz","year":"2000","edition":"3rd ed."},{"key":"2021122510314099300_R19","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1002\/(SICI)1097-0142(19971101)80:9<1803::AID-CNCR16>3.0.CO;2-9","article-title":"Union Internationale Contre le Cancer and the American Joint Committee on Cancer","volume":"80","author":"Sobin","year":"1997","journal-title":"Cancer"},{"key":"2021122510314099300_R20","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"2021122510314099300_R21","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"2021122510314099300_R22","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1200\/JCO.2010.28.0107","article-title":"Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30","volume":"29","author":"Cocks","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122510314099300_R23","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1007\/s11136-011-0082-6","article-title":"Comparing higher order models for the EORTC QLQ-C30","volume":"21","author":"Gundy","year":"2012","journal-title":"Qual Life Res"},{"key":"2021122510314099300_R24","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1007\/s11136-018-1979-0","article-title":"Cancer survivors not participating in observational patient-reported outcome studies have a lower survival compared to participants: The population-based PROFILES registry","volume":"27","author":"Rooij","year":"2018","journal-title":"Qual Life Res"},{"key":"2021122510314099300_R25","first-page":"307","article-title":"What is self-rated health and why does it predict mortality?","volume":"69","author":"Jylh\u00e4","year":"2009","journal-title":"Towards a unified conceptual model. Soc Sci Med"},{"key":"2021122510314099300_R26","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1200\/JCO.2014.57.9334","article-title":"Symptomatic toxicities experienced during anticancer treatment: Agreement between patient and physician reporting in three randomized trials","volume":"33","author":"Di Maio","year":"2015","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"2021122510314099300_R27","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1016\/j.bbi.2012.05.009","article-title":"Psychosocial intervention effects on adaptation, disease course and biobehavioral processes in cancer","volume":"30","author":"Antoni","year":"2013","journal-title":"Brain Behav Immun"},{"key":"2021122510314099300_R28","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s11136-007-9295-0","article-title":"The impact of measuring patient-reported outcomes in clinical practice: A systematic review of the literature","volume":"17","author":"Valderas","year":"2008","journal-title":"Qual Life Res"},{"key":"2021122510314099300_R29","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/1472-6963-13-211","article-title":"A systematic review of the impact of routine collection of patient reported outcome measures on patients, providers and health organisations in an oncologic setting","volume":"13","author":"Chen","year":"2013","journal-title":"BMC Health Serv Res"},{"key":"2021122510314099300_R30","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1001\/jama.288.23.3027","article-title":"Health-related quality-of-life assessments and patient-physician communication: A randomized controlled trial","volume":"288","author":"Detmar","year":"2002","journal-title":"JAMA"},{"key":"2021122510314099300_R31","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1200\/JCO.2004.06.078","article-title":"Measuring quality of life in routine oncology practice improves communication and patient well-being: A randomized controlled trial","volume":"22","author":"Velikova","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122510314099300_R32","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jama.2017.7156","article-title":"Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment","volume":"318","author":"Basch","year":"2017","journal-title":"JAMA"},{"key":"2021122510314099300_R33","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1200\/JCO.2015.63.0830","article-title":"Symptom monitoring with patient-reported outcomes during routine cancer treatment: A randomized controlled trial","volume":"34","author":"Basch","year":"2016","journal-title":"J Clin Oncol"},{"key":"2021122510314099300_R34","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s11764-017-0607-2","article-title":"Cancer survivorship monitoring systems for the collection of patient-reported outcomes: A systematic narrative review of international approaches","volume":"11","author":"Corsini","year":"2017","journal-title":"J Cancer Surviv"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2019-0348","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2019-0348","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/4\/e722\/41919397\/oncolo_25_4_e722.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/4\/e722\/41919397\/oncolo_25_4_e722.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T10:32:09Z","timestamp":1640428329000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/25\/4\/e722\/6443530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,31]]},"references-count":34,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,10,31]]},"published-print":{"date-parts":[[2020,4,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2019-0348","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,4,1]]},"published":{"date-parts":[[2019,10,31]]}}}